Nanobody Market Forecast Size, Share, Growth, Latest Trends, Global Forecast 2030
Nanobody Market Overview
According
to MRFR analysis, the global nanobody market is
expected to register a CAGR of 24.2% from 2022 to 2030 and hold a value of over
USD 1.14 billion by 2030.
The global market of nanobody is driven by various
factors, such as rising healthcare expenditure and increasing investments in
R&D activities to develop nanobody-based therapeutics. In addition,
the growing usage of nanobodies in various applications such as in vivo
imaging, antivenom therapy, and immune-based therapeutics among others is also
driving the market growth of the nanobody. Moreover, the progress of various
nanobody products in clinical trials and their subsequent approval further
boost the growth of the market. Furthermore, rising health-related concerns
coupled with favorable reimbursement policies for availing healthcare services
are anticipated to fuel the growth of the nanobody market during the forecast
period.
Nanobody Market Segmentation
The
global nanobody market has been segmented into type, application, and end user.
Based on type, the market has been segmented into
mono-specific and multi-specific. The mono-specific segment held a larger
market share in 2021. The mono-specific nanobody available in the market
incuded Cablivi (Caplacizumab) marketed by Sanofi S.A. (France). In addition,
many pharmaceutical organizations are investing in R&D for the discovery
and development of novel multi-specific nanobody drug candidates. Thus, many
multi-specific nanobody drug candidates are in various phases of clinical
trials for the treatment of cancer and other chronic diseases.
Based on application, the market has been segmented
into therapeutic, diagnostic, and research.
The therapeutic segment is further segmented into
cancer, neurodegenerative diseases, infectious diseases, and others. The
diagnostic segment is further segmented into the detection of proteins and
microorganisms, detection of small molecules, and imaging.
Based on end user, the market has been segmented
into pharmaceutical & biotechnology companies, research laboratories, and
others. The pharmaceutical & biotechnology companies segment held the
highest share in 2021, due to the rising investment in R&D activities for
the development of nanobody-based new therapeutics for the treatment of chronic
disorders such as neurodegenerative diseases, rheumatoid arthritis,
osteoporosis, and other conditions.
Nanobody Market Regional Analysis
North
America is likely to dominate the nanobody market, owing to increasing
investments in R&D by the key players & research institutes
coupled with well developed healthcare infrastructure in the
region. Furthermore, the presence of major industry players across the
region, such as Thermo Fisher Scientific Inc. (US), Sensei Biotherapeutics,
Inc. (US), Cusabio Technology LLC (US), and other players are further contributing
to the regional growth.
Europe is likely to account for a significant share
of the nanobody market due to the presence of a well-developed healthcare
infrastructure and high healthcare expenditure. For instance, according to
the Eurostat database, healthcare expenditure was 8.0% of GDP in 2020.
Moreover, the rising product approvals from regulatory bodies is also expected
to drive the growth of the market in Europe during the forecast period. For
instance, in September 2018, Cablivi (Caplacizumab) was granted marketing
authorization by the European Commission for the treatment of Acquired
Thrombotic Thrombocytopenic Purpura (aTTP) in adults.
Asia-Pacific is projected to be the fastest-growing
regional market during the forecast period due to factors like improved
healthcare infrastructure and a high percentage of the geriatric population in
the region demanding efficient therapeutics. Furthermore, initiatives
undertaken by key players to expand operations in the region are also boosting
the market growth.
Furthermore, the growth of the market in the Rest
of the World is slower compared to the other regions due to the limited
healthcare infrastructure and fewer research activities. However, increasing
government initiatives for improving the healthcare sector and the rising
prevalence of cancer and other chronic diseases are expected to drive the
market over the forecast period.
KeyPlayer
Nanobody Market
players are Sanofi S.A. (France), Merck KGaA (Germany),
Alphamab Oncology (China), Bristol Myers Squibb (US), Novartis AG
(Switzerland), GenScript Biotech Corporation (US), Sensei Biotherapeutics (US),
Beroni Group (Australia), DiosCURE Therapeutics SE (Germany), ExeVir Bio BV
(Belgium), and Taisho Pharmaceutical Holdings Co., Ltd. (Japan).
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment